



## Product acquisition from sanofi-aventis

Meda has signed an agreement with the pharmaceutical company sanofi-aventis for the acquisition of certain product rights to Imovane® (Zimovane® in some countries). The product is indicated for short-term treatment of insomnia. Imovane®/Zimovane® are well-established trademarks.

Meda will make a cash payment to sanofi-aventis of EUR 10 million for the rights in Sweden, Ireland, Belgium, Greece, Luxembourg and Cyprus. For several years, Imovane®/Zimovane® has been sold and marketed in the territory without patent protection. The annual turnover in the acquired territory is around EUR 5 million.

"This acquisition strengthens our position as a pan-European specialty pharma company", says Anders Lonner, CEO of Meda.

The European Commission has approved Meda's acquisition of Imovane®/Zimovane® from sanofi-aventis.

---

For additional information:

Meda	Anders Lonner, CEO	tel. +46 8 630 19 00
	Anders Larnholt, Investor Relations	tel. +46 8 630 19 62

Meda AB (publ) – the Swedish speciality pharma company. Meda markets prescription and over-the-counter drugs and medical equipment in about 25 countries. Meda has its own subsidiaries in the Nordic countries, the United Kingdom, Germany and the Baltic States. Meda is listed on the Stockholmsbörsen stock exchange.